Amicus Therapeutics, Inc. (LON:0HF9)
6.30
+0.21 (3.36%)
At close: Aug 1, 2025
Amicus Therapeutics Revenue
Amicus Therapeutics had revenue of $154.69M USD in the quarter ending June 30, 2025, with 22.12% growth. This brings the company's revenue in the last twelve months to $571.16M, up 25.35% year-over-year. In the year 2024, Amicus Therapeutics had annual revenue of $528.30M with 32.29% growth.
Revenue (ttm)
$571.16M
Revenue Growth
+25.35%
P/S Ratio
n/a
Revenue / Employee
$1.14M
Employees
499
Market Cap
1.47B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 528.30M | 128.94M | 32.29% |
Dec 31, 2023 | 399.36M | 70.12M | 21.30% |
Dec 31, 2022 | 329.23M | 23.72M | 7.76% |
Dec 31, 2021 | 305.51M | 44.63M | 17.11% |
Dec 31, 2020 | 260.89M | 78.65M | 43.16% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 41.24B |
GSK plc | 31.63B |
Haleon | 11.02B |
Smith & Nephew | 4.64B |
ConvaTec Group | 1.72B |
Hikma Pharmaceuticals | 2.50B |
HUTCHMED (China) | 503.39M |
Oxford Nanopore Technologies | 183.19M |
Amicus Therapeutics News
- 4 days ago - In NCLA Amicus Win, Eleventh Circuit Vacates SEC Order Used to Fund Its Illegal Collection of Data - GlobeNewsWire
- 12 days ago - Amicus Therapeutics to Announce Second Quarter 2025 Financial Results on July 31, 2025 - GlobeNewsWire
- 23 days ago - SHAREHOLDER NOTICE: Kaskela Law LLC Announces Shareholder Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Long-Term FOLD Investors to Contact the Firm - PRNewsWire
- 5 weeks ago - Amicus Therapeutics Announces Approval of Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) in Japan - GlobeNewsWire
- 6 weeks ago - U.S. Supreme Court Decision Cites NCLA's Amicus Brief in Preserving Access to Federal Courts - GlobeNewsWire
- 6 weeks ago - The Association of American Physicians and Surgeons files an Amicus Brief in the Supreme Court in Support of the Right to Conversion Therapy - GlobeNewsWire
- 7 weeks ago - In NCLA Amicus Win, Supreme Court Revives Innocent Family's Suit over FBI's Wrong-House Raid - GlobeNewsWire
- 7 weeks ago - In NCLA Amicus Win, District Court Topples Kansas Dog Kennel No-Warrant Inspection Regime - GlobeNewsWire